PTC Therapeutics signs lease with Bristol-Myers Squibb — 3 insights

Written by Eric Oliver | August 09, 2019 | Print  |

PTC Therapeutics is leasing a 185,000-square-foot biologics-focused research space from Bristol-Myers Squibb, BioPharmaReport.com reports.

What you should know:

1. PTC entered into a 15-year lease. The space includes a biologics production facility, research spaces and operations buildings.

2. PTC will develop the biologics facility to support its gene therapy production capabilities. The site is pivoting its current production schedule to create materials to support PTC's preclinical and clinical programs.

3. PTC also intends to relocate its research operations to the site.

More articles on biologics:
Why Dr. Dominic Thomas Kleinhenz joined University Orthopedics and the biggest obstacle in spine
Dr. Stephen Hochschuler: Future trends in spine – telemedicine, robotics, AI & more
Dr. Christopher Kager: The standout spine procedure in his career, future of biologics & more

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months